人乳头瘤病毒疫苗免疫接种后不良事件的系统性因果关系评估:意大利普利亚地区现行数据分析
该研究从意大利药品管理局数据库选取2008—2016年普利亚地区(约400万居民)人乳头瘤病毒疫苗接种后不良事件报告,对严重不良事件应用世界卫生组织因果关系评估标准。共登记100例不良事件(报告率17.8/10万剂),其中19例为严重事件(3.4/10万剂),12例导致住院;经评估,9例为「与免疫接种因果关系一致」,3例不确定,5例「与免疫接种因果关系不一致」,2例不可分类。作者认为仅半数严重不良事件可与疫苗接种关联,提示意大利药品管理局报告对HPV疫苗安全性呈现不完整图景。
要点
- 2008—2016年普利亚地区登记100例HPV疫苗不良事件,报告率17.8/10万剂,其中严重事件19例(3.4/10万剂)。
- 经WHO因果关系评估,9例为「与免疫接种因果关系一致」,3例不确定,5例「与免疫接种因果关系不一致」,2例不可分类。
- 住院病例中5例一致、5例不一致、1例不可分类、1例不确定;补充健康档案信息后,不确定和不可分类者转为「不一致」。
核心结论
- 仅半数严重不良事件可与疫苗接种关联,提示意大利药品管理局报告对HPV疫苗安全性呈现不完整图景,读者可能混淆「事后」与「因故」而未考虑因果关系评估结果。
- 作者认为应在不良事件监测中系统使用WHO因果关系评估算法,公共卫生工作应聚焦于提升信息质量以减少观察者间结论变异,并保证报告的常规随访以收集补充信息。
研究设计与样本
- 研究从意大利药品管理局数据库选取2008—2016年普利亚地区(约400万居民)报告的人乳头瘤病毒疫苗接种后不良事件。
- 对严重不良事件应用世界卫生组织因果关系评估标准;对住院病例,结合健康档案补充信息重复评估。
主要发现
- 2008—2016年共登记100例HPV疫苗不良事件,报告率为17.8/10万剂,其中19例为严重事件(3.4/10万剂),12例导致住院。
- 经因果关系评估,9例不良事件为「与免疫接种因果关系一致」,3例不确定,5例「与免疫接种因果关系不一致」,2例不可分类。
- 住院患者中,5例不良事件为一致,5例不一致,1例不可分类,1例不确定;补充健康档案信息后结果相似,仅不确定和不可分类不良事件转为「不一致」。
临床怎么用
- 作者认为应在不良事件监测中系统使用WHO因果关系评估算法。
- 作者认为公共卫生工作应聚焦于提升所提供信息的质量以减少观察者间结论变异,并保证报告的常规随访以收集补充信息。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since 2013, World Health Organization (WHO) recommended that adverse events following immunization (AEFIs) should be evaluated by a standardized algorithm for causality assessment, however the use of WHO procedure is rarely adopted. In Italy, AEFIs (classified only by temporal criteria) are registered in the National Drug Authority (AIFA) database, but causality assessment is not mandatory. Every year AIFA publishes the AEFIs report, that doesn't contain information about causal correlation between events and vaccines. From AIFA database, we selected AEFIs following human papillomavirus vaccination (HPV) reported in Apulia (about 4,000,000 inhabitants) during 2008-2016. For serious AEFIs, we applied WHO causality assessment criteria; for cases hospitalized, we repeated the assessment getting additional information from health documentation. In 2008-2016, 100 HPV AEFIs (reporting rate: 17.8 per 100,000 doses) were registered of which 19 were serious (rate: 3.4 per 100,000 doses) and 12 led to hospitalization. After causality assessment, for 9 AEFIs the classification was "consistent causal association to immunization", for 3 indeterminate, for 5 "inconsistent causal association to immunization" and for 2 not-classifiable. Among hospitalized patients, 5 AEFIs were consistent, 5 inconsistent, 1 not-classifiable and 1 indeterminate; adding information from health documentation, the results were similar except for indeterminate and not classifiable AEFIs that turned into "not consistent". Only half of severe AEFIs could be associated with vaccination and this suggests that AIFA report provides a incomplete picture of HPV vaccine safety, with a risk for readers to confound "post hoc" and "propter hoc" approach without considering the causality assessment results. In the view of the systematic use of WHO causality assessment algorithm in the AEFI surveillance, the efforts of Public Health must be focused on the improvement of the quality of the information provided to reduce conclusions inter-observer variability; the routine follow-up of reports, also to collect additional information, must be guaranteed.
引用
- Tafuri S, Fortunato F, Gallone MS, et al. Systematic causality assessment of adverse events following HPV vaccines: Analysis of current data from Apulia region (Italy). Vaccine. 2018. PMID: 29358055. doi:10.1016/j.vaccine.2018.01.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。